PedAM
Pediatric Disease Annotations & Medicines
| Disease | hepatitis c |
| Symptom | C0151317|chronic infection |
| Sentences | 129 |
| PubMedID- 21813371 | chronic infection with the hepatitis c virus (hcv) affects more than 3% of the world's population 1. |
| PubMedID- 23010773 | Introduction: adverse effects appearing during combined peg-interferon and ribavirin antiviral treatment against chronic infection with the hepatitis c virus are a major cause for treatment failures and abrupt interruption. |
| PubMedID- 22848445 | chronic infection with the hepatitis c virus (hcv) affects an estimated 2–3% of the world's population and is a leading cause of cirrhosis and hepatocellular carcinoma 1. |
| PubMedID- 24103591 | A markov model was used as it allows representing the relevant stages of the natural history of the disease over time, as well as estimates for probability of progression between the several health states related to the chronic infection with hepatitis c virus. |
| PubMedID- 26357610 | chronic infection with hepatitis c virus (hcv) is estimated to affect approximately 3% of the world's population and cause 350,000 deaths each year. |
| PubMedID- 21316532 | Background: cirrhosis developing during chronic infection with the hepatitis c virus (hcv) poses a risk of anticipated liver-related death, therefore representing a dominant indication to anti-hcv therapy. |
| PubMedID- 21407274 | The prevalence of chronic infection with the hepatitis c virus (hcv) in patients with chronic kidney disease is higher than in the general population. |
| PubMedID- 25888935 | chronic infection with hepatitis c virus (hcv) affects approximately 170 million people worldwide, and it is associated with increased morbidity and mortality secondary to cirrhosis and hepatocarcinoma (hcc) 1. |
| PubMedID- 20813419 | Background & aims: chronic infection with hepatitis c virus (hcv) is often associated with elevated hepatic iron levels. |
| PubMedID- 26035647 | chronic infection with hepatitis c virus (hcv) is characterized by liver fibrosis and cirrhosis, metabolic disorders (steatosis, insulin resistance, iron overload) and liver cancer . |
| PubMedID- 24713004 | chronic infection with hepatitis c virus (hcv) is a leading indicator for liver disease. |
| PubMedID- 21576430 | chronic infection with hepatitis c virus (hcv) is a major global health burden and is associated with an increased risk of liver cirrhosis and hepatocellular carcinoma. |
| PubMedID- 21680513 | chronic infection with the hepatitis c virus (hcv) is associated with increased risk for hepatocellular carcinoma (hcc). |
| PubMedID- 20106936 | An example is chronic infection with hepatitis c virus, where the initial infection may be asymptomatic for decades. |
| PubMedID- 22966221 | chronic infection with the hepatitis c virus (hcv) is a major risk factor for the development of hepatocellular carcinoma (hcc). |
| PubMedID- 20208985 | chronic infection with the hepatitis c virus (chc) in the united states is reported to have peaked at 3.6 million americans affected; however, the number of individuals with advanced fibrosis is projected to continue to rise until the year 2020 1. |
| PubMedID- 20950406 | chronic infection with the hepatitis c virus (hcv) is more prevalent than human immunodeficiency virus (hiv) infection, but more public health resources are allocated to hiv than to hcv. |
| PubMedID- 24168254 | From 2002 to 2011, the standard of care treatment for chronic infection with hepatitis c virus (hcv) was 24 or 48 weeks of therapy with pegylated interferon-alfa (peg-ifn) and ribavirin (rbv). |
| PubMedID- 22310781 | chronic infection with hepatitis c virus (hcv) is a major problem affecting a significant percentage of patients with end-stage renal failure (esrd), with a negative impact on patient survival, and associated with accelerated progression of liver damage after undergoing a kidney transplant. |
| PubMedID- 25285757 | chronic infection with hepatitis c virus (hcv) may lead to b cell activation and transformation into non-hodgkin lymphoma (nhl). |
| PubMedID- 20557368 | Two week induction of interferon-beta followed by pegylated interferon alpha-2b and ribavirin for chronic infection with hepatitis c. |
| PubMedID- 22925702 | chronic infection with hepatitis c virus (hcv) is one of the leading causes of chronic liver disease; about 170 million people worldwide are estimated to be infected. |
| PubMedID- 23230035 | Purpose: the pharmacologic properties, clinical efficacy, and safety profile of the first oral protease inhibitor approved for the treatment of chronic infection with hepatitis c virus (hcv) genotype 1 are reviewed. |
| PubMedID- 26058595 | In japan, most european countries, and america, approximately 60% of hcc cases are attributed to chronic infection with hepatitis c virus (hcv) 3. |
| PubMedID- 22830036 | chronic infection with hepatitis c virus (hcv) is an independent risk factor for developing type 2 diabetes mellitus (dm) . |
| PubMedID- 26424404 | chronic infection with hepatitis c virus (hcv) has emerged as a significant contributor to morbidity and mortality in patients infected with human immunodeficiency virus (hiv) in the era of successful antiretroviral therapy (art) implementation . |
| PubMedID- 25170193 | chronic infection with hepatitis c virus (hcv) is a leading cause of liver-related morbidity and mortality worldwide and predisposes to liver fibrosis and end-stage liver complications. |
| PubMedID- 25081062 | Background: chronic infection with hepatitis c virus (hcv) is a risk factor for liver diseases such as fibrosis, cirrhosis and hepatocellular carcinoma. |
| PubMedID- 25814250 | Approximately 3% of the worlds population suffers from chronic infections with hepatitis c virus (hcv). |
| PubMedID- 24069039 | chronic infection with hepatitis c virus (hcv) is increasingly recognized as a major global health problem (1, 2). |
| PubMedID- 22577025 | A combination of protein c and retinol-binding protein 4 in serum gave promising preliminary results as candidate biomarkers to distinguish patients at different stages of hepatic fibrosis due to chronic infection with hepatitis c virus (hcv). |
| PubMedID- 24631092 | hepatitis c virus (hcv) leads to chronic infection in the majority of infected patients presumably due to failure or inefficiency of the immune responses generated. |
| PubMedID- 24621321 | chronic infection with hepatitis c virus (hcv) affects up to 170 million individuals worldwide 1 and may lead to progressive hepatic fibrosis and cirrhosis, with risk of liver failure and hepatocellular carcinoma. |
| PubMedID- 26295392 | chronic infection with the hepatitis c virus (hcv) is a leading cause of liver-related mortality worldwide, since it is a major risk factor for the development of cirrhosis and hepatocellular carcinoma (hcc) 1. |
| PubMedID- 22899946 | chronic infection with hepatitis c virus (hcv) is associated with a wide spectrum of extrahepatic manifestations, affecting different organ systems. |
| PubMedID- 25198705 | chronic infection with hepatitis c virus (hcv) is associated with a large spectrum of extrahepatic manifestations (ehms), mostly immunologic/rheumatologic in nature owing to b-cell proliferation and clonal expansion. |
| PubMedID- 24984340 | Recently approved direct-acting antiviral agents (daa) for the treatment of chronic infection with hepatitis c virus (hcv) genotype 1, protease inhibitors (pi) boceprevir and telaprevir, have substantially increased the rates of sustained virologic response in the treatment of naive and experienced patients. |
| PubMedID- 23291588 | chronic infection with hepatitis c virus (hcv) is a common cause of liver cirrhosis and cancer. |
| PubMedID- 21461964 | chronic infections with hepatitis c virus (hcv) are frequently pronounced in the etiology of malignancies especially in hepatocellular carcinoma. |
| PubMedID- 24273918 | Background: the rate of hepatocellular carcinoma (hcc) is increasing in egypt where the major risk factor is chronic infection with hepatitis c virus (hcv). |
| PubMedID- 20163377 | Background: chronic infection with hepatitis c, genotype 2/3, responds better than other genotypes to peginterferon and ribavirin treatment. |
| PubMedID- 23869873 | Background and aim: chronic infection with hepatitis c virus (hcv) decreases health-related quality of life (hrqol). |
| PubMedID- 20513077 | Case report: cure of chronic infection with hepatitis c virus after 6 weeks of peg-interferon and ribavirin in a patient co-infected with hiv. |
| PubMedID- 25646622 | Along these lines, somewhat discouraging results have recently been reported from a phase i monotherapy trial of the hcv entry inhibitor itx-5061 given for up to 28 days in the setting of established chronic infection with the hepatitis c virus . |
| PubMedID- 22158321 | In addition to these associations, there is substantial evidence for a causativerelationship between chronic infection with hepatitis c virus (hcv) and non-hodgkinlymphoma (nhl), an association that has been the subject of several recentsystematic reviews (gisbert et al, 2003;matsuo et al, 2004; dal maso and franceschi, 2006). |
| PubMedID- 21914084 | chronic infection with hepatitis c virus (hcv) can induce insulin resistance (ir) in a genotype-dependent manner and contributes to steatosis, progression of fibrosis and resistance to interferon plus ribavirin therapy. |
| PubMedID- 21449783 | Background: peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis c virus (hcv). |
| PubMedID- 23114628 | chronic infection with hepatitis c virus (hcv) is a major contributor to the high and rising incidence of hepatocellular carcinoma (hcc) worldwide (chen & morgan, 2006). |
| PubMedID- 21741004 | Background/purpose: chronic infection with the hepatitis c virus (hcv) is associated with impaired lipid metabolism. |
| PubMedID- 24839620 | Background: chronic infection with hepatitis c virus (hcv) is a major cause of cirrhosis, hepatocellular carcinoma and liver transplantation. |